Marshall Wace
CGON icon

Marshall Wace’s CG Oncology CGON Stock Holding History

Marshall Wace’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Buy
+4,185
New +$274K ﹤0.01% 2724
2026
Q1 		– Sell
-261,110
Closed -$10.8M – 3242
2025
Q4 		$10.8M Buy
261,110
+204,733
+363% +$8.47M 0.01% 842
2025
Q3 		$2.27M Buy
+56,377
New +$1.64M ﹤0.01% 1554
2025
Q2 		– Sell
-2,418,456
Closed -$59.2M – 2749
2025
Q1 		$59.2M Buy
2,418,456
+960,384
+66% +$27M 0.08% 240
2024
Q4 		$41.8M Buy
1,458,072
+1,450,372
+18,836% +$49.6M 0.05% 322
2024
Q3 		$291K Sell
7,700
-68,282
-90% -$2.39M ﹤0.01% 2160
2024
Q2 		$2.4M Buy
+75,982
New +$2.63M ﹤0.01% 1280

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace's CGON Position: Q2 2026 in Review

Marshall Wace opened a new position in CG Oncology (CGON) in Q2 2026: 4,185 shares worth $297K. The stake represents ﹤0.01% of the portfolio and ranks #2724 among its holdings. This is a return to the name: Marshall Wace previously reported a position in CGON as recently as Q4 2025.

Marshall Wace first reported a position in CGON in Q2 2024 and has held it in 7 quarters since. The position peaked at $59.2M in Q1 2025. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Marshall Wace held 4,185 shares of CG Oncology worth $297K as of Q2 2026.
  • CG Oncology was a new Marshall Wace position in Q2 2026.
  • CG Oncology made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2724 holding.
  • Marshall Wace first reported a position in CG Oncology in Q2 2024 and has held it in 7 quarters since.
  • Marshall Wace's CG Oncology position peaked at $59.2M in Q1 2025.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.